Compare Docusign Inc (DOCU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs GeneDx Holdings Corp — how do they compare? Docusign Inc trades at $70.88 (market cap $13.35B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Docusign Inc is far larger — about 6.6× GeneDx Holdings Corp's market cap, and Docusign Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and GeneDx Holdings Corp for 19 Days on average.
| DOCU | WGS | |
|---|---|---|
Market Cap | $13.35B | $2.02B |
Volume | 3,158,858 | 734,640 |
Sector | Technology | Health |
52-Week High | $73.14 | $167.51 |
52-Week Low | $41.75 | $34.51 |
Typical Hold Time | 71 Days | 19 Days |
Enterprise Value | $12.76B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.08, up 3.16% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is solid, and profitability metrics like net income margin and ROE show significant improvement. Recent news highlights AI integration in contract processing and leadership in workflow software, though insider selling has been noted.
The outlook for DOCU is positive, driven by earnings beats and AI adoption, but risks include valuation concerns with a P/E of 43.55 and insider selling. The consensus price target of $68.75 suggests limited upside from current levels, indicating a cautious stance from analysts despite bullish technical signals.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
